Syngene International posts Q4 FY25 consolidated profit at Rs. 183.3 Cr
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Overall investment in the US facility is estimated around US$50 million
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
Investment will fund expansion to meet rising demand for CRDMO services
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Subscribe To Our Newsletter & Stay Updated